Clene Inc.

About Clene Inc.

Clene Inc. is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases by restoring and protecting neuronal health and function through nanotherapeutics that target cellular energy impairments.

Products & Services

CNM-Au8:A nanotherapeutic product aimed at addressing neurodegenerative diseases.

Nanotherapeutic Platform:A platform for creating clean-surfaced, catalytically-active nanocrystals for therapeutic use, targeting high unmet medical needs in neurodegenerative diseases.

CNM-Au8

Specialties

Nanomedicine Neurodegenerative Disease Treatment Nanotherapeutics Catalytically-active nanocrystals

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity T: - FT: Equity	A: 7000000 MR: - FA: approximately $7 million FAN: 7000000	D: 2026-05-05 FD: 2026-05-05	2 investors
2	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 28000000 MR: - FA: approximately $28 million FAN: 28000000	D: 2026-01-09 FD: 2026-01-09	3 investors
3	RT: Debt T: - FT: Debt	A: 10000000 MR: - FA: $10.0 million FAN: 10000000	D: 2024-12-19 FD: 2024-12-19	-
4	RT: Registered Direct Offering and Concurrent Private Placements T: - FT: Registered Direct Offering and Concurrent Private Placements	A: 7300000 MR: - FA: 7.3 million FAN: 7300000	D: 2024-10-01 FD: 2024-10-01	5 investors
5	RT: Registered Direct Offering and Private Placements T: - FT: Registered Direct Offering and Private Placements	A: 7300000 MR: - FA: 7.3 million FAN: 7300000	D: 2024-09-30 FD: 2024-09-30	3 investors
6	RT: Grant T: - FT: Grant	A: 45100000 MR: - FA: $45.1 million FAN: 45100000	D: 2023-10-05 FD: 2023-10-05	1 investors
7	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 40000000 MR: - FA: $40 million FAN: 40000000	D: 2023-06-21 FD: 2023-06-21	5 investors
8	RT: Public Offering T: - FT: Public Offering	A: 40000000 MR: - FA: $40 million FAN: 40000000	D: 2023-06-16 FD: 2023-06-16	3 investors

Equity Latest

2026-05-05

$7.0M

2 investors (Pro only)

Registered Direct Offering 2026-01-09

$28.0M

Debt 2024-12-19

$10.0M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Rob Etherington

President & CEO

M

Mark Mortenson

Chief Science Officer

B

Benjamin Greenberg

Head of Medical

M

Morgan Brown

Chief Financial Officer

M

Michael Hotchkin

Chief Development Officer

J

Jerry Miraglia

General Counsel and Corporate Secretary

View 42 more team members with Pro

Unlock Full Team Directory

Recent News

Clene Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised